Prof Tom John
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
170 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Impacts of Multidisciplinary Lung Cancer Meeting Presentation in a Clinical Quality Registry
DOI: 10.1016/j.jtocrr.2026.1009842026
Journal article
Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational Study
DOI: 10.1016/j.jtocrr.2026.1009782026
Journal article
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG).
DOI: 10.1016/j.jtho.2026.1036962026
Journal article
Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer
DOI: 10.1080/14796694.2026.26309842025
Journal article
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
DOI: 10.1200/JCO-25-007882025
Journal article
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.CCR-25-14492025
Research grants (ARC, NHMRC, MRFF)
A Registry-Based Randomised Trial of Radiotherapy in Advanced Lung Cancer
RECENT SCHOLARLY WORKS
2025
Other
Supplementary Table S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306181832025
Other
Supplementary Table S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306181892025
Other
Supplementary Figure S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306182042025
Other
Supplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.30618201